AAFA’s Allergy Capitals report reveals that people with seasonal pollen allergies in many parts of the U.S. may find managing their symptoms more challenging,” said Sanaz Eftekhari, AAFA’s vice ...

The approval of depemokinab, of which Exdensur is the brand name, for chronic rhinosinusitis in addition to intranasal corticosteroids by China's National Medical Products Administration follows an ...

New treatment option offers potential to reduce repeat surgeries ...

Lunsekimig, a bispecific drug aimed at two popular targets, succeeded in studies in asthma and nasal polyps but missed its mark in an eczema trial.

Sanofi SA SNY on Tuesday reported Phase 2 data for its experimental therapy lunsekimig in chronic respiratory diseases, ...

Sanofi’s TSLP and IL-13 inhibitor has aced a pair of mid-stage studies for respiratory diseases, but missed on a phase 2 ...

Sanofi’s lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP The AIRCULES phase 2b study ...

For many residents in Centennial Hills, Summerlin, Skye Canyon, Providence and Northwest Las Vegas, those environmental ...

Millions struggle with stubborn sinus trouble that feels like endless allergies, but the real cause might surprise you. It could be nasal polyps. Lifestyle Expert ...

Caneil Satchwell has been named the 2026 Youth of the Year for the Boys and Girls Clubs of Greater Tampa Bay due to his years of leadership, community service and academic success. This is the second ...

PHILADELPHIA — The investigational drug verekitug improved sinonasal symptoms, reduced nasal polyp size, and reduced the need for nasal polyp surgery in people with chronic rhinosinusitis with nasal ...